
Opinion|Videos|September 28, 2023
Available Treatments for Patients With RRMM After 4+ Prior Lines of Therapy
Author(s)Ajai Chari, MD, PhD
Dr Ajai Chari discusses the various treatments available for patients with relapsed/refractory multiple myeloma and emphasizes the paradigm-changing impact of emerging therapies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































